Insmed Inc
Research Insmed Inc (INSM) on Bullrun: market cap USD 21.51B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINSM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 21.51B
- Financial periodQ2 2026
- RevenueUSD 425.49M
- Net income-USD 13.24M
- Free cash flow-USD 95.09M
- Gross margin84.2%
Valuation Snapshot
latest market cap is USD 21.51B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 606.42M | -USD 1.28B | -USD 967.58M | 79.7% | -6.42 | USD 510.45M | USD 540.96M | USD 738.98M |
| FY2024 | USD 363.71M | -USD 913.77M | -USD 705.81M | 76.4% | -5.57 | USD 555.03M | USD 1.10B | USD 285.38M |
| FY2023 | USD 305.21M | -USD 749.57M | -USD 549.54M | 78.5% | -5.34 | USD 482.37M | USD 1.16B | -USD 331.92M |
| FY2022 | USD 245.36M | -USD 481.53M | -USD 410.32M | 77.5% | -3.91 | USD 1.07B | USD 1.13B | USD 87.95M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 21.51B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 37.29B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 12.38B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.43B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.71B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 3.23B | n/a | n/a | n/a |
About Insmed Inc
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
ETFs that hold Insmed Inc
Insmed Inc is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| Harbor Health Care UCITS ETF - Accumulating | 4.02% | 0.89% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Insmed Inc's market cap?
Insmed Inc's market capitalization is USD 21.51B.
What does Insmed Inc do?
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.